Form 4: Roivant Sciences Director Trades Common Shares

Roivant Sciences Director Melissa B. Epperly reports transactions involving the acquisition and disposition of common shares and stock options.

Summary

• Melissa B. Epperly, a Director at Roivant Sciences Ltd., has reported several transactions related to the company's common shares and stock options.
• On June 29, 2026, Epperly acquired 17,750 common shares at a price of $4.46 per share, totaling $79,155.
• On the same date, Epperly disposed of 15,002 common shares at a weighted average price of $34.32, and an additional 2,748 common shares at a weighted average price of $34.71.
• Following these transactions, Epperly beneficially owns 19,222 common shares directly.
• Additionally, Epperly was awarded 17,750 stock options to purchase common shares, which are fully vested, with an exercise price of $4.46 and an expiration date of July 19, 2032.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports routine insider transactions without providing new strategic or financial information.

Positives

• Acquisition of 17,750 common shares at a price of $4.46 per share indicates a belief in the company's value at that price point.
• The award of 17,750 fully vested stock options suggests continued incentive alignment for the director.
• The director retains a significant number of shares (19,222) after the reported dispositions.

Negatives

• Disposition of a substantial number of common shares (17,750 total) could be interpreted as a reduction in direct ownership.
• The sale of shares at prices significantly higher than the acquisition price of new shares ($34.32/$34.71 vs $4.46) indicates a realization of gains, but also a reduction in holdings.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The reported acquisition of shares at a lower price and disposition at higher prices, alongside the grant of stock options, is a common practice for executive compensation and incentive alignment within the biotechnology and pharmaceutical sectors.

Stakeholder Impact

• Shareholders: The disposition of shares by a director may be observed, but the acquisition of shares at a lower price and the retention of a significant number of shares suggest continued commitment.
• Employees: The stock option award reinforces the incentive structure for key personnel.
• Management: The transactions reflect standard executive compensation and ownership practices.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Roivant Sciences, Stock Options, Common Shares, Beneficial Ownership, Director Transactions